GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression

This study is testing a CAR-T cell therapy — immune cells genetically engineered to target a protein called GPC3 — specifically for people with advanced liver cancer (hepatocellular carcinoma, or HCC) whose tumours express this protein. **You may be eligible if...** - You have been diagnosed with advanced liver cancer (HCC) and your tumour tests positive for the GPC3 protein - Your expected survival is more than 12 weeks - Your liver function score (Child-Pugh score) is below 7, meaning your liver is functioning adequately - Your heart, lungs, liver, and kidneys are functioning well enough - Lab tests confirm your modified immune cells are working effectively against GPC3-positive targets **You may NOT be eligible if...** - You have previously received gene therapy - Your tumour does not express the GPC3 protein - Your liver or other organs are too severely affected - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.